ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.350,38
0,92%
S&P 500
5.996,66
1,00%
US Dollar vs BRL
6,08068
0,00%
Bitcoin
103.320,39
-0,77%
Brent Oil
80,005
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ocular Therapeutix Inc (OCUL)

  7. Ocular Therapeutix Inc (OCUL) Notícias

OCUL

Ocular Therapeutix (OCUL)

Ocular Therapeutix Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCUL
DataHoraFonteTítuloCódigoCompanhia
17/01/202509:00GlobeNewswire Inc.Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
14/01/202509:00GlobeNewswire Inc.Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDRNASDAQ:OCULOcular Therapeutix Inc
08/01/202509:00GlobeNewswire Inc.Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference PresentationNASDAQ:OCULOcular Therapeutix Inc
10/12/202409:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:OCULOcular Therapeutix Inc
02/12/202409:30GlobeNewswire Inc.Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1NASDAQ:OCULOcular Therapeutix Inc
27/11/202409:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
26/11/202409:30GlobeNewswire Inc.Ocular Therapeutix™ to Participate in December Investor and Scientific ConferencesNASDAQ:OCULOcular Therapeutix Inc
25/11/202420:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
14/11/202419:49Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:OCULOcular Therapeutix Inc
14/11/202411:37Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:OCULOcular Therapeutix Inc
14/11/202409:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
14/11/202409:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCULOcular Therapeutix Inc
14/11/202409:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
14/11/202409:00GlobeNewswire Inc.Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business HighlightsNASDAQ:OCULOcular Therapeutix Inc
13/11/202409:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIVNASDAQ:OCULOcular Therapeutix Inc
12/11/202409:30GlobeNewswire Inc.Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business OfficerNASDAQ:OCULOcular Therapeutix Inc
06/11/202409:30GlobeNewswire Inc.Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024NASDAQ:OCULOcular Therapeutix Inc
15/10/202408:30GlobeNewswire Inc.Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
09/10/202418:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
09/10/202408:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at October Ophthalmology MeetingsNASDAQ:OCULOcular Therapeutix Inc
25/09/202408:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024NASDAQ:OCULOcular Therapeutix Inc
05/09/202408:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at September Retina MeetingsNASDAQ:OCULOcular Therapeutix Inc
04/09/202408:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at Two Investor Conferences in SeptemberNASDAQ:OCULOcular Therapeutix Inc
09/08/202408:30GlobeNewswire Inc.Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
07/08/202408:10GlobeNewswire Inc.Ocular Therapeutix™ Reports Second Quarter 2024 ResultsNASDAQ:OCULOcular Therapeutix Inc
07/08/202408:00GlobeNewswire Inc.Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
31/07/202408:30GlobeNewswire Inc.Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024NASDAQ:OCULOcular Therapeutix Inc
30/07/202408:30GlobeNewswire Inc.Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD StudyNASDAQ:OCULOcular Therapeutix Inc
10/07/202409:00GlobeNewswire Inc.Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific MeetingNASDAQ:OCULOcular Therapeutix Inc
13/06/202417:05GlobeNewswire Inc.Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR StudyNASDAQ:OCULOcular Therapeutix Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:OCUL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
PMAM3
PARANAPANEMA ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
AMOB3
Automob Participacoes ON
BOV
BRAV3
Brava Energia ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
AMER3
Americanas ON
BOV
HBRE3
HBR Realty Empreendiment... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados